ArticleCancers2025

Plasma WFDC2 (HE4) as a Predictive Biomarker for Clinical Outcomes in Cancer Patients Receiving Anti-PD-1 Therapy: A Pilot Study.

Makoto Watanabe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.